Skip to main content
An official website of the United States government

Community Oncology and Prevention Trials

Supports clinical oncology trials in cancer prevention and control in community settings. Funds investigator-initiated research in supportive, palliative and end-of-life care. Coordinates with other NCI programs to conduct clinical oncology research projects in the community setting.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

Major Programs

Staff List

Photo Name, Email, Phone Room Group(s)/Office
Heckman-Stoddard, Brandy, Ph.D., M.P.H.
brandy.heckman-stoddard@nih.gov
240-276-7048
5E334 Chief | Breast and Gynecologic Cancer
Acting Chief | Community Oncology and Prevention Trials
Lee, Beverly
beverly.lee@nih.gov
5E532 Program Officer | Community Oncology and Prevention Trials
Lee, Cecilia, Dr.P.H., RN
cecilia.lee@nih.gov
240-276-7152
5E516 Nurse Consultant | Community Oncology and Prevention Trials
Maxwell, Pamela
pamela.maxwell@nih.gov
240-276-7081
5E434 Program Specialist | Community Oncology and Prevention Trials
McCarty, Larae
larae.mccarty@nih.gov
240-276-5777
5E322 Program Specialist | Community Oncology and Prevention Trials
Early Detection
Parker, Bernard, M.D., FACP
bernard.parker@nih.gov
240-276-5533
5E448 Program Officer | Community Oncology and Prevention Trials
Streck, Brennan, Ph.D., RN, M.P.H.
brennan.streck@nih.gov
240-276-7050
5E430 Program Officer | Breast and Gynecologic Cancer
Program Officer | Community Oncology and Prevention Trials
White, Vanessa A., M.P.H.
vanessa.white@nih.gov
240-276-6163
5E524 Program Officer | Breast and Gynecologic Cancer
Program Officer | Community Oncology and Prevention Trials
Whitman, Cynthia, B.S. [C]
cynthia.whitman@nih.gov
Contractor | Community Oncology and Prevention Trials

Grants

PI Name Sort descending PI Organization Title Grant Number Program Official
Smith, Ellen Mary Lavoie

University Of Alabama At Birmingham
United States

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study 5R01CA235726-07 Brennan Streck, Ph.D., RN, M.P.H.
Somers, Tamara J

Duke University
United States

A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial 5R01CA237892-05 Brennan Streck, Ph.D., RN, M.P.H.
Spiegel, Brennan

Cedars-Sinai Medical Center
United States

Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes 5R01CA252211-05 Rachel Altshuler, Ph.D.
Staff, Nathan P

Mayo Clinic Rochester
United States

Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity 5R01CA275870-03 Rachel Altshuler, Ph.D.
Upshaw, Jenica

Beth Israel Deaconess Medical Center
United States

A randomized trial of cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma and pre-existing cardiomyopathy or prior anthracycline exposure 1R37CA300969-01 Eileen Dimond, R.N., M.S.
Wang, Jing

New York University School Of Medicine
United States

Optimizing the use of ketamine to reduce chronic postsurgical pain 3UH3CA261067-05S1 Brennan Streck, Ph.D., RN, M.P.H.
Washington, Karla

Washington University
United States

Problem-Solving Therapy for Cancer Caregivers: A Randomized Clinical Trial in Outpatient Palliative Care 5R01CA258311-05 Brennan Streck, Ph.D., RN, M.P.H.
Xu, Chunhui

Emory University
United States

High-throughput assessment of chemotherapy-induced cardiotoxicity in 3D human cardiomyocytes 1R21CA285254-01A1 Eileen Dimond, R.N., M.S.
Yeh, Jennifer M.

Boston Children'S Hospital
United States

Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care 5R01CA261874-04 Eileen Dimond, R.N., M.S.
Yu, Anthony Francis

Sloan-Kettering Inst Can Research
United States

Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial 5R37CA273923-03 Eileen Dimond, R.N., M.S.